Breaking News

Inogen Names Kristin Caltrider as Chief Financial Officer

GOLETA, Calif.–(Small business WIRE)–Inogen, Inc. (NASDAQ: INGN), a healthcare technological know-how company providing modern respiratory goods for use in the homecare setting, now declared the appointment of Kristin Caltrider as EVP & Main Financial Officer, productive March 21, 2022. Ms. Caltrider succeeds Mike Sergesketter, who joined the Enterprise as interim CFO in December 2021, and will stay with Inogen by June 24, 2022 to facilitate a clean changeover.

Nabil Shabshab, President and Main Executive Officer of Inogen, explained, “Kristin is a confirmed govt who provides deep knowledge in top the fiscal functions of health care corporations. She has a obvious track file of partnering cross functionally to properly produce strategic designs and execute in opposition to a apparent established of monetary and enterprise ambitions to insert scale and push financially rewarding expansion. The Board and I are thrilled that she is joining us at these a pivotal time, as we get the job done to proceed the transformation of Inogen into a respiratory treatment MedTech chief, with long lasting general performance and profitability.”

Ms. Caltrider reported, “Inogen is on a great trajectory and it’s an remarkable time to be part of the Company. Inogen has a wealth of talent and a very clear chance to create on its robust platform and generate value for individuals and buyers alike. I look forward to working with the Board, Nabil and the relaxation of the management workforce to execute on the strategic program and function to place the Company for sustainable, lengthy-expression expansion.”

Mr. Shabshab ongoing, “I want to thank Mike for his steady help through our research approach for a CFO – I am grateful for his willingness to occur out of retirement to assist Inogen and for bringing his working experience and self-control to bear which we have benefited from considerably.”

Kristin A. Caltrider Biography

Ms. Caltrider joins Inogen from Quidel Company, a service provider of quick diagnostic testing solutions, mobile-centered virology assays and molecular diagnostic systems detailed on NASDAQ, where by she most a short while ago served as Vice President of Finance because June 2014. In this role, Ms. Caltrider oversaw world Finance and Accounting features, which provided all features of transactional and specialized accounting, tax and treasury, economical planning and investigation, cash management and forecasting, finance-connected M&A activities as properly as world wide analytics, and sales operations. While in that job, she served the corporation aggressively scale its production ability and appreciably grow profits and profitability. Ms. Caltrider initial joined Quidel in 2007, in which she held roles of increasing responsibility. Prior to becoming a member of Quidel, Ms. Caltrider used just about 4 yrs at Life Systems (now Thermo Fisher), where she held a variety of positions. Ms. Caltrider graduated from California Lutheran University with a bachelor’s degree in Company Administration, and also retains an MBA from the College of San Diego.

About Inogen

We are a medical technological know-how corporation supplying progressive respiratory merchandise for use in the homecare placing. We largely develop, manufacture and industry ground breaking portable oxygen concentrators used to deliver supplemental extensive-term oxygen therapy to people suffering from long-term respiratory disorders.

For a lot more information, be sure to go to www.inogen.com.

Inogen has made use of, and intends to carry on to use, its Investor Relations internet site, http://trader.inogen.com/, as a usually means of disclosing product non-general public information and for complying with its disclosure obligations beneath Regulation FD. For more information, visit http://investor.inogen.com/.

Cautionary Observe Concerning Forward-On the lookout Statements

This push release is made up of forward-hunting statements in just the meaning of the Non-public Securities Litigation Reform Act of 1995, including, between others, statements with respect to the declared modifications to management statements relating to or implying Inogen’s long term money effectiveness statements regarding Inogen’s objectives and opportunity, like the opportunity for Inogen to reach tough performance and profitability the potential of administration personnel to add to the execution of Inogen’s strategic strategies and goals and the skill of Inogen to achieve sustainable, lengthy-phrase advancement. Any statements contained in this interaction that are not statements of historic truth may be deemed to be forward-hunting statements. Phrases these as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and comparable expressions are meant to identify ahead-wanting statements. Ahead-searching statements are issue to many risks and uncertainties that could cause real outcomes to differ materially from now expected final results, such as but not minimal to, challenges related to its announced administration and organizational adjustments, and pitfalls arising from the chance that Inogen will not comprehend predicted long term economic effectiveness or strategic aims. In addition, Inogen’s enterprise is matter to quite a few extra threats and uncertainties, together with, amongst many others, dangers relating to sector acceptance of its items competition its product sales, internet marketing and distribution abilities its planned profits, marketing and advertising, and research and enhancement actions interruptions or delays in the supply of parts or supplies for, or manufacturing of, its solutions seasonal variations unanticipated will increase in prices or charges and pitfalls affiliated with worldwide functions. Data on these and more challenges, uncertainties, and other info influencing Inogen’s enterprise operating outcomes are contained in its Yearly Report on Kind 10-K for the interval finished December 31, 2021, and in its other filings with the Securities and Trade Fee. These forward-searching statements converse only as of the day hereof. Inogen disclaims any obligation to update these ahead-hunting statements besides as may be expected by law.